Performance of the 2019 ESC/EASD guideline strategy for the screening of silent coronary artery disease in patients with diabetes.
CAC score
Coronary disease
Diabetes
Myocardial scintigraphy
Silent ischemia
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
15 02 2023
15 02 2023
Historique:
received:
08
01
2023
accepted:
01
02
2023
entrez:
16
2
2023
pubmed:
17
2
2023
medline:
18
2
2023
Statut:
epublish
Résumé
The 2019 guidelines for cardiovascular risk stratification by the European Society of Cardiology and European Association for the Study of Diabetes (ESC-EASD) suggested screening for silent coronary disease in very high risk patients with severe target organ damage (TOD) (i.e. peripheral occlusive arterial disease or severe nephropathy) or high coronary artery calcium (CAC) score. This study aimed to test the validity of this strategy. In this retrospective study, we included 385 asymptomatic patients with diabetes and no history of coronary disease but with TOD or ≥ 3 risk factors in addition to diabetes. CAC score was measured using computed tomography scan and a stress myocardial scintigraphy was performed to detect silent myocardial ischemia (SMI), with subsequent coronary angiography in those with SMI. Various strategies to select patients to be screened for SMI were tested. CAC score was ≥ 100 Agatston units (AU) in 175 patients (45.5%). SMI was present in 39 patients (10.1%) and among the 30 patients who underwent angiography, 15 had coronary stenoses and 12 had a revascularization procedure. The most effective strategy consisted in performing myocardial scintigraphy in the 146 patients with severe TOD and, among the 239 other patients without severe TOD, in those with CAC ≥ 100 AU: this strategy provided 82% sensitivity for SMI diagnosis, and identified all the patients with stenoses. The ESC-EASD guidelines suggesting SMI screening in asymptomatic patients with very high risk assessed by severe TOD or high CAC score appears effective and could identify all the patients with stenoses eligible for revascularization.
Sections du résumé
BACKGROUND
The 2019 guidelines for cardiovascular risk stratification by the European Society of Cardiology and European Association for the Study of Diabetes (ESC-EASD) suggested screening for silent coronary disease in very high risk patients with severe target organ damage (TOD) (i.e. peripheral occlusive arterial disease or severe nephropathy) or high coronary artery calcium (CAC) score. This study aimed to test the validity of this strategy.
METHODS
In this retrospective study, we included 385 asymptomatic patients with diabetes and no history of coronary disease but with TOD or ≥ 3 risk factors in addition to diabetes. CAC score was measured using computed tomography scan and a stress myocardial scintigraphy was performed to detect silent myocardial ischemia (SMI), with subsequent coronary angiography in those with SMI. Various strategies to select patients to be screened for SMI were tested.
RESULTS
CAC score was ≥ 100 Agatston units (AU) in 175 patients (45.5%). SMI was present in 39 patients (10.1%) and among the 30 patients who underwent angiography, 15 had coronary stenoses and 12 had a revascularization procedure. The most effective strategy consisted in performing myocardial scintigraphy in the 146 patients with severe TOD and, among the 239 other patients without severe TOD, in those with CAC ≥ 100 AU: this strategy provided 82% sensitivity for SMI diagnosis, and identified all the patients with stenoses.
CONCLUSION
The ESC-EASD guidelines suggesting SMI screening in asymptomatic patients with very high risk assessed by severe TOD or high CAC score appears effective and could identify all the patients with stenoses eligible for revascularization.
Identifiants
pubmed: 36793073
doi: 10.1186/s12933-023-01760-4
pii: 10.1186/s12933-023-01760-4
pmc: PMC9930289
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
33Informations de copyright
© 2023. The Author(s).
Références
BMJ. 2013 Mar 25;346:f1654
pubmed: 23529983
Diabet Med. 2006 Nov;23(11):1186-91
pubmed: 17054593
JACC Cardiovasc Imaging. 2016 May;9(5):580-9
pubmed: 27085440
Diabetologia. 2020 Feb;63(2):221-228
pubmed: 31853556
Diabet Med. 2017 Sep;34(9):1244-1251
pubmed: 28419565
Am Heart J. 2007 May;153(5):807-14
pubmed: 17452158
Diabetes Care. 2011 Sep;34(9):2101-7
pubmed: 21775753
J Am Coll Cardiol. 2007 May 8;49(18):1860-70
pubmed: 17481445
J Am Soc Echocardiogr. 2022 Mar;35(3):258-266
pubmed: 34752929
Arch Cardiovasc Dis. 2019 Jan;112(1):3-11
pubmed: 30655225
Eur Heart J. 2006 Mar;27(6):713-21
pubmed: 16497686
Am J Cardiol. 1997 Jan 15;79(2):134-9
pubmed: 9193011
J Am Coll Cardiol. 2009 Nov 10;54(20):1872-82
pubmed: 19892239
J Nucl Cardiol. 2007 May-Jun;14(3):272-4
pubmed: 17556158
N Engl J Med. 2017 Apr 13;376(15):1407-1418
pubmed: 28402770
J Am Coll Cardiol. 2004 May 5;43(9):1663-9
pubmed: 15120828
Diabetes. 2001 May;50(5):1180-5
pubmed: 11334424
Arch Cardiovasc Dis. 2011 Mar;104(3):178-88
pubmed: 21497307
Diabetes Care. 2005 Nov;28(11):2722-7
pubmed: 16249546
JAMA Cardiol. 2017 Dec 1;2(12):1332-1340
pubmed: 29117273
Eur Heart J. 2020 Jan 7;41(2):255-323
pubmed: 31497854
JAMA. 2009 Apr 15;301(15):1547-55
pubmed: 19366774
Cardiovasc Diabetol. 2014 Jan 15;13:20
pubmed: 24428877
Diabetologia. 2005 Feb;48(2):379-85
pubmed: 15688207
BMJ. 2008 Jul 01;337:a236
pubmed: 18595902
Diabet Med. 2004 Apr;21(4):342-8
pubmed: 15049936
JACC Cardiovasc Imaging. 2010 Jul;3(7):734-45
pubmed: 20633852
Eur Heart J Cardiovasc Imaging. 2018 Aug 1;19(8):838-846
pubmed: 29452348
J Am Soc Nephrol. 2009 Aug;20(8):1813-21
pubmed: 19443635
J Am Coll Cardiol. 2011 Apr 12;57(15):1622-32
pubmed: 21439754
Diabetes Metab. 2010 Apr;36(2):91-6
pubmed: 20189425
Curr Cardiol Rev. 2013 Nov;9(4):331-9
pubmed: 24527682
J Am Coll Cardiol. 2018 Jul 24;72(4):434-447
pubmed: 30025580
Am J Cardiol. 2013 Mar 15;111(6):914-8
pubmed: 23276472
J Am Coll Cardiol. 1990 Mar 15;15(4):827-32
pubmed: 2407762
Diabetes Care. 2003 May;26(5):1553-79
pubmed: 12716821
Diabetes Care. 2021 Jan;44(Suppl 1):S125-S150
pubmed: 33298421
Int J Cardiol Heart Vasc. 2021 Jun 26;35:100829
pubmed: 34235245
JAMA. 2014 Dec 3;312(21):2234-43
pubmed: 25402757
N Engl J Med. 2014 Apr 17;370(16):1514-23
pubmed: 24738668
Diabetes Res Clin Pract. 2020 Jan;159:107947
pubmed: 31778747
Diabetes Care. 1999 Sep;22(9):1396-400
pubmed: 10480499
Circulation. 2004 Jul 6;110(1):22-6
pubmed: 15210604
Diabetes. 1993 Jul;42(7):1017-25
pubmed: 8513969